Papers › AntBO: Towards Real-World Automated Antibody Design with Combinatorial Bayesian Optimisation
AntBO: Towards Real-World Automated Antibody Design with Combinatorial Bayesian Optimisation
Asif Khan, Alexander I. Cowen-Rivers, Antoine Grosnit, Derrick-Goh-Xin Deik, Philippe A. Robert, Victor Greiff, Eva Smorodina, Puneet Rawat, Kamil Dreczkowski, Rahmad Akbar, Rasul Tutunov, Dany Bou-Ammar, Jun Wang, Amos Storkey, Haitham Bou-Ammar
Antibodies are canonically Y-shaped multimeric proteins capable of highly specific molecular recognition. The CDRH3 region located at the tip of variable chains of an antibody dominates antigen-binding specificity. Therefore, it is a priority to design optimal antigen-specific CDRH3 regions to develop therapeutic antibodies. However, the combinatorial nature of CDRH3 sequence space makes it impossible to search for an optimal binding sequence exhaustively and efficiently using computational approaches. Here, we present AntBO: a combinatorial Bayesian optimisation framework enabling efficient in silico design of the CDRH3 region. Ideally, antibodies are expected to have high target specificity and developability. We introduce a CDRH3 trust region that restricts the search to sequences with favourable developability scores to achieve this goal. For benchmarking, AntBO uses the Absolut! software suite as a black-box oracle to score the target specificity and affinity of designed antibodies in silico in an unconstrained fashion. The experiments performed for 159 discretised antigens used in Absolut! demonstrate the benefit of AntBO in designing CDRH3 regions with diverse biophysical properties. In under 200 calls to black-box oracle, AntBO can suggest antibody sequences that outperform the best binding sequence drawn from 6.9 million experimentally obtained CDRH3s and a commonly used genetic algorithm baseline. Additionally, AntBO finds very-high affinity CDRH3 sequences in only 38 protein designs whilst requiring no domain knowledge. We conclude AntBO brings automated antibody design methods closer to what is practically viable for in vitro experimentation.
In Syntology View this paper on Syntology, its page in Syntology's graph. That page lists the repositories linked to the paper, the abstract and the calls for agents.
Open this paper in Syntology's Atlas, the map of the papers in Syntology's graph and their citations.
For agents, on Syntology's MCP service (how to connect):
get_citation_path(paper_1="2201.12570", paper_2="…")with another paper's arXiv id or titleget_concepts_for_paper(arxiv_id="2201.12570")
Code
Repository list and official/mentioned flags are the archive's, frozen 2025-07-28. Reachability, where shown, is from one Syntology probe window (2026-09-16 to 2026-09-18); repositories not probed show nothing. GitHub stars are not tracked.
A paper named beside a repository with no sample linked to this paper is shown with that paper's own run record, not this paper's: “ran” means executed on a synthesized input, not that the code is correct, and “where Syntology's instrument failed” counts failures of Syntology's instrument, not of the code. Papers are listed in arXiv-id order, at most three per repository.
Code Syntology ran Syntology
Not run by Syntology. Nothing on this page verifies that the listed code works.
Tasks
Results from the paper archive 2025-07-28
No leaderboard rows for this paper in the archive.
Report a problem or propose a change · a person checks every report against the paper or source before anything changes; decisions are listed on /corrections